PGR and neoplasm: As part of their standard care, all patients underwent a core needle biopsy prior to treatment to confirm the cancer diagnosis; determine the histological subtype; and assess hormone receptor status, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) in order to classify the tumor’s molecular subtype.